Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Financing Activities (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Cash from Financing Activities for 4 consecutive years, with $9.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 458.15% to $9.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $15.4 million, a 338.44% increase, with the full-year FY2024 number at $5.6 million, up 1731.26% from a year prior.
  • Cash from Financing Activities was $9.3 million for Q3 2025 at bioAffinity Technologies, up from $3.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $15.0 million in Q3 2022 to a low of -$563556.0 in Q4 2022.
  • A 4-year average of $2.2 million and a median of $301363.0 in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 127.65% in 2023, then skyrocketed 3412.08% in 2025.
  • bioAffinity Technologies' Cash from Financing Activities stood at -$563556.0 in 2022, then skyrocketed by 84.95% to -$84805.0 in 2023, then surged by 2488.86% to $2.0 million in 2024, then skyrocketed by 361.18% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Cash from Financing Activities are $9.3 million (Q3 2025), $3.0 million (Q2 2025), and $1.0 million (Q1 2025).